ID: ALA3087302

Max Phase: Preclinical

Molecular Formula: C11H8ClNO2S

Molecular Weight: 253.71

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C1NC(=O)/C(=C/c2ccccc2Cl)CS1

Standard InChI:  InChI=1S/C11H8ClNO2S/c12-9-4-2-1-3-7(9)5-8-6-16-11(15)13-10(8)14/h1-5H,6H2,(H,13,14,15)/b8-5+

Standard InChI Key:  NKXNCVZOWAYPDG-VMPITWQZSA-N

Associated Targets(Human)

CCRF-CEM 65223 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MDA-MB-231 73002 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Vero 26788 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

B16-F10 4610 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

L1210 27553 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 253.71Molecular Weight (Monoisotopic): 252.9964AlogP: 2.71#Rotatable Bonds: 1
Polar Surface Area: 46.17Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 11.54CX Basic pKa: CX LogP: 2.83CX LogD: 2.83
Aromatic Rings: 1Heavy Atoms: 16QED Weighted: 0.78Np Likeness Score: -0.88

References

1. Ferreira M, Assunção LS, Filippin-Monteiro FB, Filippin-Monteiro FB, Creczynski-Pasa TB, Sá MM..  (2013)  Synthesis of 1,3-thiazine-2,4-diones with potential anticancer activity.,  70  [PMID:24177368] [10.1016/j.ejmech.2013.10.017]

Source